Your browser doesn't support javascript.
loading
Safety and Efficacy of the Addition of Lapatinib to Perioperative Chemotherapy for Resectable HER2-Positive Gastroesophageal Adenocarcinoma: A Randomized Phase 2 Clinical Trial.
Smyth, Elizabeth C; Rowley, Samuel; Cafferty, Fay H; Allum, William; Grabsch, Heike I; Stenning, Sally; Wotherspoon, Andrew; Alderson, Derek; Crosby, Tom; Mansoor, Was; Waters, Justin S; Neville-Webbe, Helen; Darby, Suzanne; Dent, Jo; Seymour, Matthew; Thompson, Joyce; Sothi, Sharmila; Blazeby, Jane; Langley, Ruth E; Cunningham, David.
Affiliation
  • Smyth EC; Department of Gastrointestinal Oncology and Lymphoma, Royal Marsden Hospital, London and Surrey, United Kingdom.
  • Rowley S; Department of Oncology,Cambridge University Hospitals, NHS Foundation Trust, Hill's Road, Cambridge, United Kingdom.
  • Cafferty FH; Medical Research Council, Clinical Trials Unit, University College London, United Kingdom.
  • Allum W; Medical Research Council, Clinical Trials Unit, University College London, United Kingdom.
  • Grabsch HI; Department of Surgery, Royal Marsden Hospital, London and Surrey, United Kingdom.
  • Stenning S; Department of Pathology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center+, Maastricht, the Netherlands.
  • Wotherspoon A; Division of Pathology and Data Analytics, Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, United Kingdom.
  • Alderson D; Medical Research Council, Clinical Trials Unit, University College London, United Kingdom.
  • Crosby T; Department of Pathology, Royal Marsden Hospital, London and Surrey, United Kingdom.
  • Mansoor W; Department of Surgery, Queen Elizabeth Hospital, Birmingham, United Kingdom.
  • Waters JS; Velindre Cancer Centre, Cardiff, United Kingdom.
  • Neville-Webbe H; Department of Medical Oncology, Christie Hospital, Manchester, United Kingdom.
  • Darby S; Kent Oncology Centre, Maidstone Hospital, Kent, United Kingdom.
  • Dent J; Clatterbridge Cancer Centre, Wirral, United Kingdom.
  • Seymour M; Department of Oncology, Weston Park Hospital, Sheffield, United Kingdom.
  • Thompson J; Department of Oncology, Huddersfield Royal Infirmary, Huddersfield, United Kingdom.
  • Sothi S; Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, United Kingdom.
  • Blazeby J; Heart of England NHS Trust, Birmingham, United Kingdom.
  • Langley RE; Department of Oncology,University Hospitals, Coventry, United Kingdom.
  • Cunningham D; Bristol Centre for Surgical Research, Population Health Sciences, University of Bristol, Bristol, United Kingdom.
JAMA Oncol ; 5(8): 1181-1187, 2019 Aug 01.
Article in En | MEDLINE | ID: mdl-31219517
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Type of study: Clinical_trials / Prognostic_studies Language: En Journal: JAMA Oncol Year: 2019 Type: Article Affiliation country: United kingdom
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Type of study: Clinical_trials / Prognostic_studies Language: En Journal: JAMA Oncol Year: 2019 Type: Article Affiliation country: United kingdom